"Dusting" Versus "Basketing" - Treatment Of Intrarenal Stones

Sponsor
Mayo Clinic (Other)
Overall Status
Completed
CT.gov ID
NCT01619735
Collaborator
(none)
178
9
50.3
19.8
0.4

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate outcomes of an established procedure for treatment of kidney stones that are present within the inner aspect of the kidney. This procedure is called flexible ureteroscopy, which involves placing a small camera through the urethra while anesthetized (asleep), up the ureter (the tube connecting kidney and bladder) and into the kidney to the kidney stone. Then, the stone is broken into tiny fragments using a small laser called a Holmium laser. While this treatment is a well-established option for treatment of these stones, there are several different techniques used to help eliminate them from the kidney. Some urologists treat the stone by a method called "active" extraction whereby the ureteroscope is passed back and forth into the kidney to remove all visible stone fragments. Others use a method called "dusting" whereby the stones are broken into tiny fragments or "dust" with the intention that achieving such a small stone size will allow the stones to pass spontaneously. There has not been a systematic and rigorous comparison of these techniques in terms of treatment outcomes. By collecting information on the success of treatment, the investigators hope to provide benchmark data for future studies of kidney stone treatment and improve the care of all patients who need surgery for their kidney stones.

The investigators hypothesize that the stone free rate for renal stone(s) 5-15 mm is around 90% and that the stone clearance rate with be 20% higher in those patients that undergo complete stone fragment extraction versus those that undergo stone dusting (residual fragments < 2mm).

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    To date, there is inadequate literature to confidently determine the ideal technique of stone extraction during ureteroscopy, an endourologic procedure for the treatment of kidney stones. The goals of ureteroscopy for intrarenal stones are to fragment stones and minimize residual fragments while doing so in a safe and expeditious way with minimal harm to the patient. Options for the treatment of intrarenal stones consist of using a basket to pull them out or a laser to break them into small fragments. When stones are deemed too large to be basketed primarily, the standard preference in ureteroscopic laser lithotripsy is use of the Holmium:YAG laser which can effectively break stones into fragments small enough to remove or pass spontaneously.

    There is no consensus on how to achieve optimal stone clearance once the primary stone is fragmented with lithotripsy. Many urologists choose to "dust" the stone by breaking it into tiny fragments < 1 - 2 mm in size with the assumption that stone fragments of such a small size will pass spontaneously after surgery. This can theoretically decrease operative times and lower risk of ureteral trauma by minimizing repetitive introduction and removal of the ureteroscope. Others choose to actively extract each possible stone fragment during the procedure thereby increasing the immediate stone-free outcome.

    Active extraction however typically increases costs as it requires use of a basket or grasper and ureteral access sheath. To date, only one prospective, randomized study has addressed the practice of active extraction vs spontaneous passage, the results of which suggested higher rates of residual stone fragments, hospital readmissions and need for ancillary procedures when stones were not actively extracted (8). This study was criticized for not following a standardized operative protocol and not reporting several important outcomes including stone composition. Additionally, this study used semirigid ureteroscopy, specifically addressed ureteral rather than intrarenal stones, and did not follow a "dusting" protocol assuring minimal size of residual fragments.

    Complete eradication of stone fragments is one of the primary outcomes of ureteroscopy as residual renal stone fragments after ureteroscopy have been shown to lead to a subsequent stone event in approximately 20% of cases(9). However, maximizing eradication of stone fragments must not come at the expense of the patient. For this reason it is important to consider the operative variables associated with the different techniques employed to clear stone during such procedures.

    For example, an average of nearly three times as much laser energy was used to fragment the stone into tiny pieces compared to active extraction (8). Conversely, active extraction of stone fragments requires introducing and removing the ureteroscope through the ureter a greater number of times in order to facilitate stone removal; which generally requires use of a ureteral access sheath, a treatment with its own associated risk.(10). The short term and long term differences resulting from use of these techniques is currently unknown.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    178 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Ureteroscopic Treatment of Intrarenal Stones - A Comparative Analysis of "Dusting" Versus "Basketing" With Holmium Laser Lithotripsy
    Study Start Date :
    Apr 1, 2013
    Actual Primary Completion Date :
    Mar 22, 2017
    Actual Study Completion Date :
    Jun 10, 2017

    Arms and Interventions

    Arm Intervention/Treatment
    Fragments basketed

    "Active" extraction is whereby the ureteroscope is passed back and forth into the kidney to remove all visible stone fragments.

    Fragments dusted

    "Dusting" is whereby the stones are broken into tiny fragments or "dust" with the intention that achieving such a small stone size will allow the stones to pass spontaneously.

    Outcome Measures

    Primary Outcome Measures

    1. Stone-free rate [4-6 weeks post-operatively]

      To assess for stone-free rate using K.U.B. (kidney-ureter-bladder) plain radiograph and renal ultrasound. If there is a discrepancy in follow up imaging between the presence of residual stones or fragments between the KUB and renal ultrasound, the KUB will be considered the reference standard for small fragments less than 4mm unless the stone composition is uric acid. If fragments 5 mm or larger exist it will be up to the discretion of the surgeon to order a CT to better delineate the presence of residual stones and their impact on the clinical management of that patient.

    Secondary Outcome Measures

    1. Stone recurrence rate [12 months post operatively]

      Stone recurrence rate one year after surgery

    2. Retreatment rate [12 months post operatively]

      Evaluating the retreatment rate one year post operation

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Radiopaque renal stones above the level of the ureteropelvic junction

    • Kidney stones must range up to 20 mm in size or in the case of multiple stones the conglomerate diameter (additive maximal diameter of all stones on axial imaging of computed tomography) up to 20 mm is required for inclusion

    • Patient must be a suitable operative candidate for flexible ureteroscopy

    Exclusion Criteria:
    • Patients who have had prior ipsilateral upper urinary tract reconstructive procedures or history of ipsilateral ureteral stricture

    • Patients who have undergone prior radiotherapy to the abdomen or pelvis and those who have a neurogenic bladder or spinal cord injury

    • Pregnant subjects

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Mayo Clinic Scottsdale Arizona United States 85259
    2 UCSD San Diego California United States 92103
    3 James Buchanan Brady Urological Institute Baltimore Maryland United States 21287
    4 Massachusetts General Hospital Boston Massachusetts United States 02114
    5 Bellevue Hospital New York New York United States 10016
    6 Cleveland Clinic Cleveland Ohio United States 44195
    7 Ohio State University Columbus Ohio United States 43210
    8 Vanderbilt University School of Medicine Nashville Tennessee United States 37232
    9 University of British Columbia Vancouver British Columbia Canada

    Sponsors and Collaborators

    • Mayo Clinic

    Investigators

    • Principal Investigator: Mitchell Humphreys, MD, Mayo Clinic

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Mitchell Humphreys, Consultant - Urology (surgical)/Associate Professor of Urology, Mayo Clinic
    ClinicalTrials.gov Identifier:
    NCT01619735
    Other Study ID Numbers:
    • 12-002553
    First Posted:
    Jun 14, 2012
    Last Update Posted:
    Sep 18, 2018
    Last Verified:
    Sep 1, 2018
    Keywords provided by Mitchell Humphreys, Consultant - Urology (surgical)/Associate Professor of Urology, Mayo Clinic
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 18, 2018